Equities

Arcutis Biotherapeutics Inc

ARQT:NSQ

Arcutis Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.14
  • Today's Change-0.26 / -2.50%
  • Shares traded4.40m
  • 1 Year change+55.28%
  • Beta1.1861
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments272410387
Total Receivables, Net268.460.36
Total Inventory137.51--
Prepaid expenses191114
Other current assets, total0.931.231.54
Total current assets330437403
Property, plant & equipment, net3.904.605.30
Goodwill, net------
Intangibles, net6.447.19--
Long term investments------
Note receivable - long term------
Other long term assets0.600.080.08
Total assets341449408
LIABILITIES
Accounts payable128.837.35
Accrued expenses352926
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities473833
Total long term debt20219872
Total debt20219872
Deferred income tax------
Minority interest------
Other liabilities, total4.234.124.80
Total liabilities253240110
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,071930706
Retained earnings (accumulated deficit)(982)(720)(408)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00(1.09)(0.26)
Total equity89210298
Total liabilities & shareholders' equity341449408
Total common shares outstanding976150
Treasury shares - common primary issue00.020.09
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.